Prevalence of metabolic syndrome among patients with schizophrenia in Palestine

Waleed Sweileh's picture
Journal Title, Volume, Page: 
BMC Psychiatry 2012, 12:235 doi:10.1186/1471-244X-12-235
Year of Publication: 
Waleed M Sweileh*, Sa’ed H Zyoud, Salah A Dalal, Sami Ibwini, Ansam F Sawalha andIyad Ali
Preferred Abstract (Original): 
Waleed M Sweileh*Sa’ed H ZyoudSalah A DalalSami IbwiniAnsam F Sawalha andIyad Ali


Metabolic syndrome (MS) is a cluster of the most dangerous cardiac risk factors and is associated with high mortality. Ethnic differences in metabolic syndrome (MS) criteria and prevalence rates have been reported. The purpose of this study was to investigate the MS prevalence among patients with schizophrenia in Palestine.


We recruited 250 patients with schizophrenia from 4 psychiatric primary healthcare centers in Northern Palestine. The MS prevalence was assessed based on National Cholesterol Education Program Adult Treatment Panel III Adapted criteria.


The overall MS prevalence was 43.6%, with 39% in male and 55.9% in female patients. On average, the study patients had 2.3 ± 1.3 metabolic abnormalities. Univariate analysis showed that MS was significantly higher with older age, female gender, longer duration of the illness, smoking, abdominal obesity, high systolic and diastolic blood pressure, high triglycerides, low HDL-C, and high fasting plasma glucose. Multiple logistic regression analysis showed that only systolic blood pressure, high triglycerides, high fasting plasma glucose, and low HDL-C were significant predictors of MS in schizophrenic patients.


MS is common among Arab patients with schizophrenia. Patients with schizophrenia should receive regular monitoring and adequate treatment of cardio-metabolic risk factors.


Schizophrenia; Metabolic syndrome; Palestine

Prevalence_of_metabolic_syndrome_among_patients_with_Schizophrenia_in_Palestine__.pdf185.39 KB